SureTrader Stock Hero Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator the submariner, Inoviorulez, pistol1p
Search This Board:
Last Post: 4/18/2015 2:11:17 PM - Followers: 86 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
Wiki
RXII News: RXi Pharmaceuticals Issues Open Letter to Shareholders 12/22/2014 07:02:00 AM
RXII News: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of En... 12/17/2014 07:02:00 AM
PostSubject
#1762  Sticky Note FBR Capital rates RXII a "Hold" rating with Inoviorulez 04/09/15 01:56:19 PM
#1806   Agreed, and also a good opportunity to buy Titan V 04/18/15 02:11:17 PM
#1805   Read up on financing deals to discover why microchips 04/18/15 12:49:40 PM
#1804   If it is shorting it could be done The Other Guy 04/17/15 11:52:39 AM
#1803   Im not talking about selling. This is being buddygray 04/17/15 11:43:14 AM
#1802   Tang is selling. It is well documented on The Other Guy 04/17/15 11:19:23 AM
#1801   Is Tang shorting? buddygray 04/17/15 10:48:08 AM
#1800   Tang The Other Guy 04/17/15 10:37:32 AM
#1799   Someone is still throwing a ton of shorted buddygray 04/17/15 10:31:52 AM
#1798   Does the gap get filled this morning? Is The Other Guy 04/17/15 10:17:50 AM
#1797   They owe me a lot of Money. mr10001 04/17/15 10:02:21 AM
#1796   Not bad news but they released one month Titan V 04/17/15 09:53:26 AM
#1795   buy 4k shares for test virus0011 04/17/15 09:53:10 AM
#1794   We need to get back Over $2.00 mr10001 04/17/15 09:25:53 AM
#1793   400k shares traded in pre-market. Up 15c. The Other Guy 04/17/15 09:13:06 AM
#1792   A day late in the delivery of this The Other Guy 04/17/15 08:24:52 AM
#1791   RXi Pharmaceuticals Receives Orphan Drug Designation for Samcyprone™ Inoviorulez 04/17/15 07:58:11 AM
#1790   I sure don't see anything snuck in< could gdog 04/16/15 06:13:22 PM
#1789   Dude, you catch the details! #3 is The Other Guy 04/16/15 05:43:07 PM
#1788   Schedule 14a SEC fling filed for June 1, Inoviorulez 04/16/15 05:36:01 PM
#1787   Well I guess we know what price the The Other Guy 04/16/15 03:58:19 PM
#1786   RXI Pharma (RXII) receives FDA orphan status for samcyprone Inoviorulez 04/16/15 09:52:44 AM
#1785   Not to mention, if only half of the The Other Guy 04/16/15 09:18:27 AM
#1784   Agreed. With the S-1, the RXII market cap The Other Guy 04/16/15 09:09:33 AM
#1783   Even after the S-1. The float and AS the submariner 04/16/15 08:47:10 AM
#1782   Now 30k pre-market The Other Guy 04/16/15 08:37:38 AM
#1781   14k in pre-market trading at 75c. The Other Guy 04/16/15 08:20:47 AM
#1780   If institutions grab all of this offering...the upside the submariner 04/15/15 09:08:01 AM
#1779   Hard to sell 20 million worth of stock Tcom 04/14/15 10:51:41 PM
#1778   shorty smells blood which gives us that buying op Tcom 04/14/15 10:48:20 PM
#1777   Shares on Sale today. pistol1p 04/14/15 10:31:21 PM
#1776   Looking to grab some on this dip. GMONEY4 04/14/15 01:17:26 PM
#1775   Nice catch..Looks like they have a plan with Tcom 04/14/15 09:24:14 AM
#1774   "RXII is actually selling directly the shares to The Other Guy 04/14/15 09:12:25 AM
#1773   Wouldn't surprise me,with the low float..if the offering the submariner 04/14/15 08:01:03 AM
#1772   Thanks for the DD Bio, I didn't read Titan V 04/13/15 08:44:22 PM
#1771   The $20 million dollars in dilution and warrants Inoviorulez 04/13/15 08:40:14 PM
#1770   http://stks.co/e22Vq Titan V 04/13/15 06:53:25 PM
#1769   Great dd for the board inovio..and stock looking the submariner 04/13/15 10:08:24 AM
#1768   The collaborations with MirImmune ( I guess some Inoviorulez 04/10/15 06:26:12 PM
#1767   Haha nice. Looks like its heading back up steadily. Titan V 04/10/15 03:20:28 PM
#1766   A nickel a day keeps the doctor away. The Other Guy 04/10/15 03:03:19 PM
#1765   broke thru that .75 cap..moving on up Tcom 04/10/15 10:58:59 AM
#1764   I'll take half of the target price! There The Other Guy 04/09/15 04:33:13 PM
#1763   inovio..Great find..stickied it up. the submariner 04/09/15 03:20:47 PM
#1762   FBR Capital rates RXII a "Hold" rating with Inoviorulez 04/09/15 01:56:19 PM
#1761   catching a bid here today..might be ready Tcom 04/08/15 01:35:46 PM
#1760   $RXII recent news/filings stocktrademan 04/08/15 10:38:07 AM
#1759   Wow! NICE Goldmind 04/07/15 03:10:55 PM
#1758   Another Collaboration agreement using Rxi's sd-rxRNA platform. I Inoviorulez 04/07/15 07:12:51 AM
#1757   This is just sad. cinders118 04/06/15 10:09:11 AM
PostSubject